Diabetes, Obesity & Metabolism最新文献

{"title":"Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.","authors":"Ali Kapan, Othmar Moser, Richard Felsinger, Thomas Waldhoer, Sandra Haider","doi":"10.1111/dom.16548","DOIUrl":"https://doi.org/10.1111/dom.16548","url":null,"abstract":"<p><strong>Aims: </strong>This cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions.</p><p><strong>Materials and methods: </strong>Four hundred and eleven adults on Wegovy® (n = 217), Ozempic® (n = 148) and Mounjaro® (n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes and appetite-related outcomes. Multivariable logistic regression was used to assess associations between taste changes and satiety, appetite and craving.</p><p><strong>Results: </strong>Participants (69.6% female; median age 39 [interquartile range, IQR 33-47]) had baseline body mass index (BMI) of 35.6 (Wegovy®), 34.7 (Ozempic®) and 36.2 kg/m² (Mounjaro®). Adjusted models for baseline BMI, treatment duration, dose, age and sex showed significant reductions in BMI of 17.6% (95% CI: 15.7-19.5) for Wegovy®, 17.4% (15.0-19.8) for Ozempic® and 15.5% (8.8-22.2) for Mounjaro®. Reduced appetite was reported by 58.4% of participants (Wegovy®: 54.4%, Ozempic®: 62.1%, Mounjaro®: 56.5%) and increased satiety by 63.5% (Wegovy®: 66.8%, Ozempic®: 58.8%, Mounjaro®: 63.1%). Additionally, 21.3% reported increased sweet taste perception and 22.6% reported increased salty taste perception. Independent of the type of therapy, increased sweet taste perception was significantly associated with increased satiety (adjusted odds ratios [AOR] = 2.02; 95% CI: 1.15-4.57), decreased appetite (AOR = 1.67; 95% CI: 1.04-3.25) and decreased craving (AOR = 1.85; 95% CI: 1.05-3.29). Increased salty taste perception was associated with increased satiety (AOR = 2.17; 95% CI: 1.16-5.17; all p < 0.05).</p><p><strong>Conclusions: </strong>Self-reported changes in taste perception during GLP-1 or dual GIP/GLP-1 RAS therapy were associated with favourable appetite-related outcomes, suggesting a potential mechanism contributing to treatment response.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worldwide burden of metabolic risk-related cardiovascular disease from 1990 to 2021, with projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021.","authors":"Xinjiang Dong, Jia Wang, Chao Wang, Beibei Wang, Gang Li, Jiefu Yang, Tong Zou","doi":"10.1111/dom.16529","DOIUrl":"https://doi.org/10.1111/dom.16529","url":null,"abstract":"<p><strong>Aims: </strong>This study presents a detailed examination of specific metabolic risk factors for various types of cardiovascular disease (CVD) from 1990 to 2021, stratified by sex, age and socio-demographic index (SDI) levels, and to predict the future trajectory up to 2050.</p><p><strong>Materials and methods: </strong>Data from the Global Health Data Exchange were utilized to estimate the burden of metabolic risk-related CVD, including high low-density lipoprotein cholesterol (LDL-c), high systolic blood pressure (SBP), high fasting plasma glucose (FPG), high body mass index (BMI) and kidney dysfunction, across different types of CVD. The study employed the age-standardized death rate (ASDR)/crude death rate and its estimated annual percentage change (EAPC) to measure the burden, and a Bayesian age-period-cohort model (BAPC) to forecast future trends.</p><p><strong>Results: </strong>Globally, in 2021, the ASDR for high SBP-related CVD was 125.33 per 100 000 population, with the largest share attributed to ischaemic heart disease (IHD) (56.73) and ischaemic stroke (IS) (25.57). The ASDR for high BMI-related CVD was 22.77 per 100 000 population, with the largest share attributed to IHD (11.71) and hypertensive heart disease (HHD) (7.21). The ASDR for high FPG-related CVD was 26.85 per 100 000 population, with the largest share attributed to IHD (16.27) and IS (8.11). The ASDR for high LDL-c-related CVD was 43.67 per 100 000 population, including IHD (32.29) and IS (11.38). The ASDR for kidney dysfunction-related CVD was 25.55 per 100 000 population, with the largest share also attributed to IHD (17.18) and IS (4.24). From 1990 to 2021, the EAPCs for high BMI-related HHD, intracerebral haemorrhage, subarachnoid haemorrhage and atrial fibrillation/flutter, as well as high FPG-related lower extremity peripheral arterial disease, increased. However, the EAPCs for most metabolic risk-related CVD declined, with varying EAPCs across different risk factors, sexes, age groups and SDI levels. Projected increases in CVD deaths related to all metabolic risks are expected by 2050, with significant variations in ASDR trends.</p><p><strong>Conclusions: </strong>This study provides a comprehensive analysis of the historical and projected burden of metabolic risk-related CVD, highlighting the need for targeted interventions to mitigate the escalating challenges posed by these diseases and their impact on global health systems.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.","authors":"Clare Buckeridge, Sonia Cobain, Harold E Bays, Osamu Matsuoka, Yasushi Fukushima, Patricia Halstead, Nikolaos Tsamandouras, Nicole Sherry, Donal N Gorman, Aditi R Saxena","doi":"10.1111/dom.16534","DOIUrl":"10.1111/dom.16534","url":null,"abstract":"<p><strong>Aims: </strong>This randomized, double-blind, placebo-controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity.</p><p><strong>Materials and methods: </strong>Eligible participants (aged 18-75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo twice daily (BID) for 26 or 32 weeks. Danuglipron was escalated to doses of 40-200 mg BID in 1-, 2-, or 4-week intervals. Assessments included body weight, waist circumference, and safety evaluations.</p><p><strong>Results: </strong>Overall, 628 participants were randomized; of 626 receiving study treatment (placebo, n = 90; danuglipron, n = 536), 39.3% completed treatment. Approximately 38% of participants discontinued treatment because of adverse events (AEs) and 22% discontinued for other reasons. The primary endpoint was the change in weight from baseline to the end of treatment; all danuglipron groups demonstrated statistically significant reductions with least squares mean percentage decreases from baseline ranging from -5.0% (90% confidence interval [CI] -6.8%, -3.2%) to -12.9% (90% CI -16.1%, -9.5%) relative to placebo. Danuglipron was considered safe. Consistent with the mechanism, the most frequently reported events were nausea and vomiting, and increased rates of gastrointestinal AEs were generally observed at higher doses. Most events were reported as mild, and no other dose-related trends were observed in safety endpoints.</p><p><strong>Conclusions: </strong>In participants with obesity, danuglipron resulted in statistically significant and clinically meaningful reductions in body weight versus placebo over 26 or 32 weeks. The overall safety profile observed in this study was consistent with expectations for the mechanism, although discontinuation rates due to AEs were higher than anticipated across all treatment groups, including placebo.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT04707313.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediterranean diet vs. the Australian guide to healthy eating (AGHE) on body composition and glucose metabolism: A randomized controlled trial.","authors":"Robel Hussen Kabthymer, Jessica Danaher, Barbora de Courten","doi":"10.1111/dom.16458","DOIUrl":"10.1111/dom.16458","url":null,"abstract":"<p><strong>Aims: </strong>The Mediterranean diet has been extensively studied and shown to reduce chronic disease risk. The Australian Guide to Healthy Eating (AGHE) offers a balanced dietary framework tailored to Australian habits, yet its comparative efficacy with the Mediterranean diet remains unexplored. Thus, this study aims to compare the efficacy of the Mediterranean diet with AGHE on body composition and glucose metabolism.</p><p><strong>Materials and methods: </strong>We conducted a randomised controlled trial including 57 participants (median age 31, IQR: 25-37 years; 71.9% female, BMI = 25.1 kg/m²), with 23 participants randomised to the Mediterranean diet and 34 participants to the AGHE diet for eight weeks. Paired t-tests were employed for within-group comparisons, and analysis of covariance (ANOVA) was used for between-group comparisons, adjusted for age and baseline observations.</p><p><strong>Results: </strong>The Mediterranean diet intervention resulted in a significant decrease in waist circumference (-1.3 cm, p = 0.043), body fat percentage (-1.8%, p = 0.014), resting metabolic rate (RMR) (-17.9 kcal/day, p = 0.02) and fasting insulin concentration (-1.2 μIU/mL, p = 0.016), along with an increase in body lean mass percentage (1.7%, p = 0.015) compared to the AGHE group.</p><p><strong>Conclusion: </strong>The Mediterranean diet demonstrated greater efficacy in improving body composition and maintaining metabolic variables than the AGHE. These findings may support the use of the Mediterranean diet in improving health outcomes related to obesity and metabolic disorders. However, larger, well-designed clinical trials are needed to confirm these findings and explore underlying mechanisms.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond BRI: Critical reflections on cardiovascular risk assessment in metabolic syndrome.","authors":"Jian Li, Fa Gao, Aidong Liu","doi":"10.1111/dom.16539","DOIUrl":"https://doi.org/10.1111/dom.16539","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction between dietary omega-3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials.","authors":"Bing Cao, Yutong Sun, Chifong Lam, Yalin Chen, Christine E Dri, Roger S McIntyre","doi":"10.1111/dom.16535","DOIUrl":"https://doi.org/10.1111/dom.16535","url":null,"abstract":"<p><p>Emerging research underscores the potential of omega-3 polyunsaturated fatty acids (PUFAs) in weight reduction and modulation of the gut microbiota. The current review systematically examines the effects of omega-3 PUFA supplementation on body weight regulation and gut microbiota modulation in high-fat diet (HFD)-induced obesity models. The study protocol was registered with PROSPERO (CRD42024559835). Systematic searches were conducted from database inception to May 2025 on PubMed/Embase, Web of Science and selected reference lists. A total of 32 trials were included, with 25 studies employing a HFD along with dietary omega-3 PUFA supplementation and 7 studies with a HFD prior to dietary omega-3 PUFA supplementation. Omega-3 PUFA interventions consistently demonstrated attenuation of HFD-induced weight gain and adiposity, though body weight remained elevated compared to low-fat diet controls. Omega-3 PUFA supplementation also induced significant gut microbiota compositional changes. Specifically, omega-3 PUFAs effectively reduced the Firmicutes/Bacteroidetes (F/B) ratio, reversing a hallmark feature of HFD-induced dysbiosis. Enrichment of beneficial taxa, such as Akkermansia muciniphila, Bifidobacterium and Lactobacillus, was consistently observed, correlating with enhanced short-chain fatty acid (SCFA) production, improved gut barrier integrity and reduced systemic inflammation. Concurrently, omega-3 PUFAs suppressed pathogenic bacteria, such as Desulfovibrio and Lachnoclostridium, which are associated with endotoxaemia and metabolic dysfunction. These preclinical evidence suggest the potential of omega-3 PUFAs as a promising dietary intervention for obesity management through gut microbiota modulation. However, variability in outcomes across studies emphasizes the need for further investigation into the optimal duration, dosage and sources of omega-3 supplementation. Moreover, the synergistic effects of omega-3 PUFA supplements and lifestyle interventions, such as high-intensity interval training (HIIT), which further regulates microbial composition and improves metabolic outcomes, are also highly promising.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of diabetic ketoacidosis in patients with insulin-deficient diabetes phenotype initiating SGLT2 inhibitors.","authors":"Anat Tsur, Gil Leibowitz, Matan J Cohen, Avivit Cahn, Rena Pollack","doi":"10.1111/dom.16545","DOIUrl":"https://doi.org/10.1111/dom.16545","url":null,"abstract":"<p><strong>Aims: </strong>To identify predictors of diabetic ketoacidosis (DKA) in patients with an insulin-deficient phenotype initiating sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy.</p><p><strong>Materials and methods: </strong>This retrospective cohort study analysed data from 31 900 patients with diabetes aged 18-70 identified as having an insulin-deficient phenotype. After applying inclusion and exclusion criteria, patients were matched and divided into SGLT2i users (n = 6572) and non-users (n = 6382). The primary endpoint was the first DKA event in patients with no prior history of DKA. Independent risk factors for DKA were assessed using Cox regression.</p><p><strong>Results: </strong>Over a median follow-up of 4.4 years, 239 patients experienced DKA (143 [2.22%] SGLT2i users vs. 96 [1.54%] non-users; HR [95% confidence interval, CI] 1.39 [1.07-1.79]; p = 0.014). The adjusted model confirmed an increased DKA risk with SGLT2i use (adjusted hazard ratio, aHR [95% CI] 1.50 [1.15-1.95]; p = 0.003). Baseline HbA1c >9% was associated with a 53% higher risk (aHR [95% CI] 1.53 [1.18-1.99]; p = 0.0016), while body mass index (BMI) ≤25 kg/m² was linked to a 61% increased risk (aHR [95% CI] 1.61 [1.24-2.09]; p = 0.0003). Insulin use further heightened risk (aHR [95% CI] 2.35 [1.71-3.23]; p < 0.0001).</p><p><strong>Conclusions: </strong>SGLT2i use in patients with an insulin-deficient phenotype is associated with increased DKA risk, particularly in those with HbA1c >9% and BMI ≤25 kg/m². Clinicians should exercise caution in these patients, carefully assessing risks and implementing mitigation strategies to ensure safe use.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2 diabetes and depression via microvascular dysfunction, neurodegeneration, inflammation, advanced glycation end products (AGEs), arterial stiffness.","authors":"Indra L M Steens, Miranda T Schram, Alfons J H M Houben, Tos T J M Berendschot, Annemarie Koster, Hans Bosma, Simone J P M Eussen, Bastiaan E de Galan, Thomas T van Sloten","doi":"10.1111/dom.16527","DOIUrl":"https://doi.org/10.1111/dom.16527","url":null,"abstract":"<p><strong>Aims: </strong>Type 2 diabetes increases the risk of depression, but the mechanisms underlying this association are incompletely understood. We investigated whether microvascular dysfunction, neurodegeneration, low-grade inflammation, advanced glycation end products (AGEs) and arterial stiffness, pathologies that are more common in diabetes, explain, or mediate the association between type 2 diabetes and incident clinically relevant depressive symptoms.</p><p><strong>Materials and methods: </strong>We used prospective data from The Maastricht Study, a population-based cohort study. Diabetes status and potential mediators were assessed at baseline. Clinically relevant depressive symptoms (PHQ-9 score ≥10) were assessed at baseline and each year during a median of 8.1 (IQR 4.2, 10.1) years of follow-up. Mediation analysis was employed to investigate the mediating effect of microvascular dysfunction (retinal, blood and MRI biomarkers), neurodegeneration (retina and MRI biomarkers), low-grade inflammation (blood biomarkers), AGEs (skin and blood biomarkers) and arterial stiffness (tonometry and ultrasound biomarkers).</p><p><strong>Results: </strong>Data of 6091 participants (age, 59.4 years [SD 8.6]; 51.3% women; 23.6% type 2 diabetes) were available. Type 2 diabetes was associated with a higher incidence of clinically relevant depressive symptoms (HR:1.37; 95% CI 1.13, 1.65). This association was partly mediated by microvascular dysfunction (proportion mediated:10.4% [95% CI:3.6%, 17.2%]); neurodegeneration (proportion mediated:12.1% [95% CI: 3.9%, 20.3%]); AGEs (proportion mediated:5.4% [95% CI: 3.0%, 8.8%]); and arterial stiffness (proportion mediated:8.4% [95% CI: 3.3%, 13.5%]); but not by low-grade inflammation.</p><p><strong>Conclusions: </strong>The association between type 2 diabetes and a higher risk of clinically relevant depressive symptoms is partly mediated by microvascular dysfunction, neurodegeneration, AGEs and arterial stiffness.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144323976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.","authors":"Andreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, Georgios K Dimitriadis, Marine Bertrand, Tristan Curteis, Laura J Clark, Ludi Fan, Helene Sapin, Jean-Francois Bergmann","doi":"10.1111/dom.16508","DOIUrl":"10.1111/dom.16508","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims: &lt;/strong&gt;This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Participants had body mass index (BMI) ≥ 27 kg/m&lt;sup&gt;2&lt;/sup&gt;, with ≥1 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (HbA1c) 7%-10% on stable therapy. A heterogeneity assessment confirmed that study and patient baseline characteristics were similar. Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides. Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Plain language summary: &lt;/strong&gt;What is the context and purpose of this research study? Excess weight and type 2 diabetes (T2D) are strongly connected, where most patients with T2D have obesity or overweight. Weight management is crucial for improving T2D outcomes and preventing its progression. Weight management comprises behavioural interventions, psychological support, dietary changes and physical activity programmes. Medications may also be prescribed or surgical options may also be considered. Two such medications for weight management are tirzepatide (up to 15 mg) and semaglutide (up to 2.4 mg), which are injected subcutaneously once per week to help control appetite by prolonging patients' feeling of fullness. These medications are also used at different doses to treat T2D. Because there were no clinical trials directly comparing tirzepatide and semaglutide, particularly in patients with both T2D and either obesity or overweight, this study aimed to indirectly compare the effectiveness and safety of tirzepatide and semaglutide for wei","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between retinal microvasculature and cerebral small vessel function in type 2 diabetes: An ultrahigh field MRI study.","authors":"Jan F de Leijer, Stanley D T Pham, Tessa A C M Vissers, Lieza G Exalto, Reinier O Schlingemann, Jeroen S W Siero, Jaco J M Zwanenburg, Rafael Simó, Noemi Lois, Thomas T van Sloten, Geert Jan Biessels","doi":"10.1111/dom.16546","DOIUrl":"10.1111/dom.16546","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}